Healthy
Conditions
Brief summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of orally administrated DWP10292 in healthy male volunteers.
Interventions
DRUGDWP10292
Drug: DWP10292 tablets, oral administration, single administration
DRUGPlacebo
Placebo tablets, oral administration, single administrations
Sponsors
Daewoong Pharmaceutical Co. LTD.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* A subject who provided written informed consent to participate in this study and cooperative with regard to compliance with study related constraints * Healthy adult male subjects aged 20 to 45 years * The subject has a Body weight ≥ 60 kg and \< 90 kg and Body Mass Index (BMI) ≥ 18.5 kg/m2 and \< 27.0 kg/m2 * A Subject who was judged to be healthy by the investigator to participate in this study based on screening results (according to standard reference index updated recently)
Exclusion criteria
* A subject with sign or symptoms or previously diagnosed disease of liver (viral hepatitis), digestive system, cardiovascular, kidney, respiratory, endocrinology, neurology, immune system, hematology, and psychology function or other significant diseases and history or suspicion of current drug abuse and alcohol abuse * A subject who shows vital signs with the number of systolic blood pressure of ≥140 mmHg or ≤100 mmHg, and the number of diastolic blood pressure of ≥90mmHg or ≤60mmHg * A subject who shows the following result in clinical laboratory test: * AST,ALT\>1.25 times of the upper limit of normal range * QTc\>430msec * T.bil\>1.25 times of the upper limit of normal range * A subject from whom over 400mL of blood was sampled(whole blood or plasma donation, etc.) within last 8 weeks * Subject who has taken other clinical or licensed medication from another clinical trial within an 8-week period prior to the first administration of the study medication (The last administration of the medication is considered as an end point of the previous clinical trial). * Subject who smokes an average of 10 cigarettes/day and is unable to quit smoking during the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite of Pharmacokinetics | 0 (predose), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24 (2d 0h), 36, 48 (3d 0h), 60, 72 (4d 0h), 96 h(5d 0h) and Post study visit 216h (10d 0h) | Cmax, AUClast, AUCinf, Tmax, t1/2, CL/F |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety&tolerability | 0 (predose), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24 (2d 0h), 36, 48 (3d 0h), 60, 72 (4d 0h), 96 h(5d 0h) Post study visit 216h (10d 0h) | Adverse events, Physical exam, Vital sign, laboratory(CBC,chemistry,U/A etc) |
Countries
South Korea
Outcome results
None listed